Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia Advises 475,000 Bowel Cancer Retests After Kits Questioned

This article was originally published in PharmAsia News

Executive Summary

Australia's Health Department has advised nearly half a million patients to undergo new tests for bowel cancer after kits they used came under question. The department said the tests in question, supplied by Dorevitch Pathology, returned a possibly excessive amount of negative results. Suspicions were raised about the test when the level of positive results, more than 100,000 since last December, was lower than expected. The government plans to notify the 475,000 people who have used the self-test bowel kits since Dec. 1, 2008, advising them to be retested. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071600

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel